LVP software of the Ivenix Infusion System (IIS), LVP-SW-0004
Published March 20, 2024 · Recall initiated: September 16, 2022
Summary
FDA records medical device Class II recall Z-1282-2024, published March 20, 2024 and initiated September 16, 2022. Recalling firm: Fresenius Kabi USA, LLC; Status: Completed; Reported quantity: 3; Lot: UDI-DI 00811505030122 Software versions 5.0.1 and earlier. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Completed — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Retroactively reported correction from 2022: A software defect may cause an incorrect (Fail-Stop) Alarm when an administration set is loaded with an upstream occlusion present, resulting in a non-recoverable (Fail-Stop) Pump Problem alarm. This may lead to delay of therapy, and patient may experience from no to minimal to serious harm. This issue was resolved in all fielded product in software version 5.2.1, which was installed in September 2022.
What to do
Voluntary: Firm initiated · Other
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Fresenius Kabi USA, LLC
- Distributor
- US Nationwide distribution in the states of WI and NJ.
- Lot
- UDI-DI 00811505030122 Software versions 5.0.1 and earlier.
- Risk classification
- Class II
- Area (FDA)
- device
- Country
- United States
Related recalls
- FDATyenne (tocilizumab-aazg) Injection, 400 mg/20 mL (20 mg/mL), 20 mL vial, Rx Only, Manufactured by FreseniusSeptember 2, 2026
- FDAMorphine Sulfate Injection, USP, 2 mg /mL, 1 mL single-dose Simplist prefilled syringes, For Intramuscular orAugust 26, 2026
- FDAGlycopyrrolate Injection, USP, 1 mg per 5 mL (0.2 mg per mL), 25 x 5 mL fill in a 6.5 mL vial, Rx only,July 29, 2026
- FDAXylocaine (lidocaine HCl Injection, USP), 1%, 200 mg per 20 mL (10 mg per mL), 25 Multiple-Dose Vials, 20 mL,July 29, 2026
- FDAADVIA Centaur Erythropoietin (EPO) Assay (100 Test)March 20, 2024
- FDALVP software of the Ivenix Infusion System (IIS); LVP-SW-0004March 20, 2024
Questions about this recall
Was LVP software of the Ivenix Infusion System (IIS), LVP-SW-0004 recalled?
Yes. FDA published recall Z-1282-2024 on March 20, 2024. Reported hazard: Retroactively reported correction from 2022: A software defect may cause an incorrect (Fail-Stop) Alarm when an administration set is loaded with an upstream occlusion present, resulting in a non-recoverable (Fail-Stop) Pump Problem alarm. This may lead to delay of therapy, and patient may experience from no to minimal to serious harm. This issue was resolved in all fielded product in software version 5.2.1, which was installed in September 2022.
What should I do if I have this product?
Voluntary: Firm initiated · Other